Literature DB >> 21371437

Elevated invasive potential of glioblastoma stem cells.

Lin Cheng1, Qiulian Wu, Olga A Guryanova, Zhi Huang, Qian Huang, Jeremy N Rich, Shideng Bao.   

Abstract

Glioblastomas (GBMs) are the most lethal and common types of primary brain tumors. The hallmark of GBMs is their highly infiltrative nature. The cellular and molecular mechanisms underlying the aggressive cancer invasion in GBMs are poorly understood. GBM displays remarkable cellular heterogeneity and hierarchy containing self-renewing glioblastoma stem cells (GSCs). Whether GSCs are more invasive than non-stem tumor cells and contribute to the invasive phenotype in GBMs has not been determined. Here we provide experimental evidence supporting that GSCs derived from GBM surgical specimens or xenografts display greater invasive potential in vitro and in vivo than matched non-stem tumor cells. Furthermore, we identified several invasion-associated proteins that were differentially expressed in GSCs relative to non-stem tumor cells. One of such proteins is L1CAM, a cell surface molecule shown to be critical to maintain GSC tumorigenic potential in our previous study. Immunohistochemical staining showed that L1CAM is highly expressed in a population of cancer cells in the invasive fronts of primary GBMs. Collectively, these data demonstrate the invasive nature of GSCs, suggesting that disrupting GSCs through a specific target such as L1CAM may reduce GBM cancer invasion and tumor recurrence.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371437      PMCID: PMC3065536          DOI: 10.1016/j.bbrc.2011.02.123

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

Review 1.  Potential therapeutic implications of cancer stem cells in glioblastoma.

Authors:  Lin Cheng; Shideng Bao; Jeremy N Rich
Journal:  Biochem Pharmacol       Date:  2010-05-10       Impact factor: 5.858

2.  Medical oncology: treatment and management of malignant gliomas.

Authors:  Deric M Park; Sith Sathornsumetee; Jeremy N Rich
Journal:  Nat Rev Clin Oncol       Date:  2010-02       Impact factor: 66.675

3.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.

Authors:  Shideng Bao; Qiulian Wu; Sith Sathornsumetee; Yueling Hao; Zhizhong Li; Anita B Hjelmeland; Qing Shi; Roger E McLendon; Darell D Bigner; Jeremy N Rich
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

4.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

5.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Authors:  Jeongwu Lee; Svetlana Kotliarova; Yuri Kotliarov; Aiguo Li; Qin Su; Nicholas M Donin; Sandra Pastorino; Benjamin W Purow; Neil Christopher; Wei Zhang; John K Park; Howard A Fine
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma.

Authors:  Rossella Galli; Elena Binda; Ugo Orfanelli; Barbara Cipelletti; Angela Gritti; Simona De Vitis; Roberta Fiocco; Chiara Foroni; Francesco Dimeco; Angelo Vescovi
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

8.  Cancerous stem cells can arise from pediatric brain tumors.

Authors:  Houman D Hemmati; Ichiro Nakano; Jorge A Lazareff; Michael Masterman-Smith; Daniel H Geschwind; Marianne Bronner-Fraser; Harley I Kornblum
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-26       Impact factor: 11.205

9.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

10.  L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers.

Authors:  Nancy Gavert; Maralice Conacci-Sorrell; Daniela Gast; Annette Schneider; Peter Altevogt; Thomas Brabletz; Avri Ben-Ze'ev
Journal:  J Cell Biol       Date:  2005-02-14       Impact factor: 10.539

View more
  99 in total

1.  Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

Authors:  Youngmi Kim; Eunhee Kim; Qiulian Wu; Olga Guryanova; Masahiro Hitomi; Justin D Lathia; David Serwanski; Andrew E Sloan; Robert J Weil; Jeongwu Lee; Akiko Nishiyama; Shideng Bao; Anita B Hjelmeland; Jeremy N Rich
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

3.  CEREBRAL ORGANOIDS AS A MODEL FOR GLIOBLASTOMA MULTIFORME.

Authors:  Nathaniel Silvia; Guohao Dai
Journal:  Curr Opin Biomed Eng       Date:  2020-03-25

4.  Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.

Authors:  M Venere; P Hamerlik; Q Wu; R D Rasmussen; L A Song; A Vasanji; N Tenley; W A Flavahan; A B Hjelmeland; J Bartek; J N Rich
Journal:  Cell Death Differ       Date:  2013-10-11       Impact factor: 15.828

Review 5.  Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.

Authors:  Drew A Spencer; Jacob S Young; Deepak Kanojia; Julius W Kim; Sean P Polster; Jason P Murphy; Maciej S Lesniak
Journal:  Ther Deliv       Date:  2015

6.  A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity.

Authors:  Jaroslaw Maciaczyk; Ulf D Kahlert; Katharina Koch; Rudolf Hartmann; Julia Tsiampali; Constanze Uhlmann; Ann-Christin Nickel; Xiaoling He; Marcel A Kamp; Michael Sabel; Roger A Barker; Hans-Jakob Steiger; Daniel Hänggi; Dieter Willbold
Journal:  Cell Death Discov       Date:  2020-04-16

7.  PNIPAAm-co-Jeffamine® (PNJ) scaffolds as in vitro models for niche enrichment of glioblastoma stem-like cells.

Authors:  John M Heffernan; James B McNamara; Sabine Borwege; Brent L Vernon; Nader Sanai; Shwetal Mehta; Rachael W Sirianni
Journal:  Biomaterials       Date:  2017-05-06       Impact factor: 12.479

8.  Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma.

Authors:  Zhenzhen Liu; Hongli Li; Lian He; Yu Xiang; Chengsen Tian; Can Li; Peng Tan; Ji Jing; Yanpin Tian; Lupei Du; Yun Huang; Leng Han; Minyong Li; Yubin Zhou
Journal:  Cell Chem Biol       Date:  2019-01-10       Impact factor: 8.116

Review 9.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

10.  Comparison of L1 expression and secretion in glioblastoma and neuroblastoma cells.

Authors:  Weijiang Zhao
Journal:  Oncol Lett       Date:  2012-07-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.